发明名称 |
Antibody/drug conjugates and methods of use |
摘要 |
The invention relates to conjugates that bind to targets, methods of using conjugates that bind to targets and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies that express a target. |
申请公布号 |
US9492563(B2) |
申请公布日期 |
2016.11.15 |
申请号 |
US201314067819 |
申请日期 |
2013.10.30 |
申请人 |
ESPERANCE PHARMACEUTICALS, INC. |
发明人 |
Leuschner Carola;Alila Hector |
分类号 |
A61K39/395;A61K47/48;C07K16/28;C07K16/32 |
主分类号 |
A61K39/395 |
代理机构 |
Pillsbury Winthrop Shaw Pittman LLP |
代理人 |
Pillsbury Winthrop Shaw Pittman LLP |
主权项 |
1. An antibody conjugate, comprising an antibody that binds to CD20 or CD19, wherein the antibody is linked to two or more lytic domains, wherein said lytic domains comprises or consists of a peptide selected from KFAKFAKKFAKFAKK, KFAKFAKKFAKFAKKF, KFAKFAKKFAKFAKKFA, KFAKFAKKFAKFAKKFAK, KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA (SEQ. ID. NOs. 1-6, respectively), or a peptide selected from KFAKFAKKFAKFAKK, KFAKFAKKFAKFAKKF, KFAKFAKKFAKFAKKFA, KFAKFAKKFAKFAKKFAK, KFAKFAKKFAKFAKKFAKF and KFAKFAKKFAKFAKKFAKFA (SEQ. ID. NOs. 1-6, respectively) having one or more of the F, A, or K residues of the lytic domain substituted with a corresponding D-amino acid; and wherein one of said lytic domains is linked to the amino(NH2)-terminus of a Light (L) chain of the antibody, and the other of said lytic domains is linked to the amino(NH2)-terminus of a Heavy (H) chain of the antibody. |
地址 |
Houston TX US |